BCTX

Business Context and Reporting Period

Company: BriaCell Therapeutics Corp. (BCTX)
Filing Type: Form 8-K (Current Report)
Date of Report: January 3, 2025
Reporting Period: Event-based filing regarding a corporate action announced on January 3, 2025.

Key Financial Metrics

This filing is a Current Report (Form 8-K) detailing a corporate governance event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.

Material Changes

The primary material change announced is a reverse stock consolidation approved by the Board of Directors:

• Consolidation Ratio: 1 post-Consolidation Common Share for every 15 pre-Consolidation Common Shares.
• Purpose: To ensure continued compliance with The Nasdaq Capital Market listing requirements.
• Regulatory Status: Subject to approval by the Toronto Stock Exchange (TSX).

Outlook, Management Commentary, and Risks

Timeline and Implementation:

• Expected Effective Date: January 24, 2025.
• Trading Commencement: Post-Consolidation shares expected to commence trading on the TSX and Nasdaq at market open on January 29, 2025.
• Conditions: Final trading dates are subject to confirmation from the TSX and Nasdaq.

Management Commentary: The Board approved the consolidation specifically to maintain listing compliance. No additional forward-looking guidance or risk factors beyond the standard regulatory approval contingencies are detailed in this specific filing text.

Investor Verification Checklist

• Verify the final approval status of the consolidation by the Toronto Stock Exchange (TSX).
• Confirm the official trading start date for post-Consolidation shares on January 29, 2025, via Nasdaq and TSX announcements.
• Review the attached Press Release (Exhibit 99.1) for details on the treatment of fractional shares and warrant adjustments.
• Monitor subsequent filings for updated financial statements to assess the company's liquidity position post-consolidation.